4-氰基-2-甲基苯甲酸 | 1975-53-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基-2-甲基苯甲酸
• 英文名称: 4-Cyano-2-methylbenzoic acid
• CAS: 1975-53-7
• 化学式: C₉H₇NO₂
• mdl: MFCD14582960
• 分子量: 161.16
• InChiKey: NIDKGLRXRBFGEN-UHFFFAOYSA-N

物化性质

• 沸点：
  354.7±30.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Cyano-2-methylbenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Cyano-2-methylbenzoic acid
CAS number: 1975-53-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H7NO2
Molecular weight: 161.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氰基-2-甲基苯甲酸 在 氯化亚砜 、 4-甲基苯磺酸吡啶 、 臭氧 、 N,N-二甲基甲酰胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 甲苯 为溶剂， 反应 19.92h， 生成 4-(2-(4-cyano-2-methylphenyl)-3-(4-methoxyphenyl)-1H-pyrrol-1-yl)-2-hydroxybenzoic acid
  参考文献：
  名称：

  基于吡咯的S-亚硝基谷胱甘肽还原酶抑制剂的结构-活性关系：吡咯区域异构体和丙酸替代

  摘要：

  小号-Nitrosoglutathione还原酶（GSNOR）是醇脱氢酶家族（ADH）的成员，其调节的电平小号通过分解代谢-nitrosothiols（SNOS）小号-nitrosoglutathione（GSNO）。GSNO和SNO与许多疾病的发病机制有关，包括呼吸系统，心血管和胃肠系统疾病。基于吡咯的N6022最近被鉴定为有效，选择性，可逆和有效的GSNOR抑制剂，目前正在临床研究中。我们在这里描述了新型的基于吡咯的N6022类似物的合成和结构-活性关系（SAR）专注于支架改性和丙酸替代。我们使用基于结构的方法鉴定了具有吡咯区域异构体作为支架的同等效力和新颖的GSNOR抑制剂。

  DOI：

  10.1016/j.bmcl.2011.04.086
• 作为产物：
  描述：

  4-溴-2-甲基苯甲酸 在 氯化亚砜 、 水 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 4-氰基-2-甲基苯甲酸
  参考文献：
  名称：

  基于吡咯的S-亚硝基谷胱甘肽还原酶抑制剂的结构-活性关系：吡咯区域异构体和丙酸替代

  摘要：

  小号-Nitrosoglutathione还原酶（GSNOR）是醇脱氢酶家族（ADH）的成员，其调节的电平小号通过分解代谢-nitrosothiols（SNOS）小号-nitrosoglutathione（GSNO）。GSNO和SNO与许多疾病的发病机制有关，包括呼吸系统，心血管和胃肠系统疾病。基于吡咯的N6022最近被鉴定为有效，选择性，可逆和有效的GSNOR抑制剂，目前正在临床研究中。我们在这里描述了新型的基于吡咯的N6022类似物的合成和结构-活性关系（SAR）专注于支架改性和丙酸替代。我们使用基于结构的方法鉴定了具有吡咯区域异构体作为支架的同等效力和新颖的GSNOR抑制剂。

  DOI：

  10.1016/j.bmcl.2011.04.086

文献信息

• N-acylamino acid amide compounds and intermediates for preparation thereof
  申请人：Ube Industries, Ltd.

  公开号：US06265418B1

  公开（公告）日：2001-07-24

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• Substituted Indoles
  申请人：AbbVie Inc.

  公开号：US20170174688A1

  公开（公告）日：2017-06-22

  The invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  该发明提供了以下式（I）的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 和R 6 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由SUV420H1介导和调节的疾病和症状中作为药剂是有用的。还提供了由一个或多个式（I）化合物组成的药物组合物。
• [EN] NOVEL CYSTOBACTAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE CYSTOBACTAMIDES
  申请人：HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH

  公开号：WO2019038405A1

  公开（公告）日：2019-02-28

  The present invention relates to novel derivatives of cystobactamides of formula (lb) and the use thereof for the treatment or prophylaxis of bacterial infections.

  本发明涉及公式（lb）的半胱菌肽的新颖衍生物及其用于治疗或预防细菌感染的用途。
• [EN] ARYL DICARBOXAMIDES<br/>[FR] ARYL-DICARBOXAMIDES
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2005011685A1

  公开（公告）日：2005-02-10

  The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycernia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an airninocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R1 and R2 are independently from each other is selected from the group consisting of hydrogen or C1-C6-alkyl; R4 and R5 are each independently from each other selected from the group consisting of H, hydroxy, C1-C6 alkyl, carboxy, C1-C6 alkoxy, C1-C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

  本发明涉及式(I)的芳基二羧酰胺及其用于治疗和/或预防肥胖和/或由胰岛素抵抗或高血糖介导的代谢紊乱的使用，包括I型和/或II型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、多囊卵巢综合征(PCOS)。特别是，本发明涉及使用式(I)的芳基二羧酰胺调节，尤其是抑制PTPs的活性。A是氨基甲酰基团；Cy是芳基、杂芳基、芳基-杂芳基、杂芳基-芳基、芳基-芳基、环烷基或杂环组；n为0或1；R1和R2独立地选自由氢或C1-C6-烷基组成的组；R4和R5各自独立地选自由H、羟基、C1-C6烷基、羧基、C1-C6烷氧基、C1-C3烷基羧基、C2-C3烯基羧基、C2-C3炔基羧基、氨基组成的组，或者R4和R5可以形成一个不饱和或饱和的杂环，其中至少R4或R5不是氢或C1-C6烷基。